Gregory L. Shiferman - 24 Mar 2025 Form 4 Insider Report for Sage Therapeutics, Inc. (SAGE)

Role
Senior Vice President, General Counsel and Secretary
Signature
Brandon Marsh, attorney in fact for Gregory Shiferman
Issuer symbol
SAGE
Transactions as of
24 Mar 2025
Net transactions value
-$649
Form type
4
Filing time
26 Mar 2025, 16:36:43 UTC
Previous filing
25 Feb 2025
Next filing
11 Apr 2025
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction SAGE Common Stock Tax liability $649 -79 -0.26% $8.21 30,680 24 Mar 2025 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 On March 24, 2025, the reporting person vested 235 shares of time-based restricted stock units (RSUs) granted on October 28, 2021 under the Sage Therapeutics, Inc. 2014 Stock Option and Incentive Plan. This grant vested 25% on September 24, 2022, and vests quarterly thereafter in twelve equal installments. Represents shares withheld to satisfy tax withholding obligations on the vesting of restricted stock units.

Remarks:

Senior Vice President, General Counsel and Secretary